{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:25:13Z","timestamp":1777929913466,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T00:00:00Z","timestamp":1240358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T00:00:00Z","timestamp":1240358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>Die in der Literatur mitgeteilte nicht-h\u00e4matologische Toxizit\u00e4t bei hochdosierter Cytarabin-Therapie betra\u00ed in erster Linie ZNS (zerebellare St\u00f6rungen), Augen (Keratitis und Konjunktivitis), Haut (Erythem) und Verdauungstrakt (Erbrechen, Diarrhoen). Sie ist teils von der Dosis, teils von der Behandlungsdauer abh\u00e4ngig. Eine Dosis von 48 g\/m2 f\u00fcr einen Zyklus stellt offensichtlich eine kritische Obergrenze dar, da von hier ab insbesondere die Ge\u00edahr einer irreversiblen Hirnsch\u00e4digung w\u00e4chst. Ber\u00fccksichtigt man die Tatsache, da\u00df die Indikation \u00ed\u00fcr hochdosiertes Cytarabin vor allem die prognostisch ung\u00fcnstigen Prim\u00e4rversager und Rezidive bei akuten Leuk\u00e4mien betraf, so scheint die Toxizit\u00e4t akzeptabel zu sein.<\/jats:p>","DOI":"10.1159\/000215604","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T10:40:22Z","timestamp":1240396822000},"page":"20-22","source":"Crossref","is-referenced-by-count":0,"title":["Nicht-h\u00e4matologische Toxizit\u00e4t bei der hochdosierten Cytarabin-Therapie"],"prefix":"10.1159","author":[{"given":"R.","family":"Kuse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"K\u00fcchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,22]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/215604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000215604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:57:25Z","timestamp":1777679845000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000215604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,22]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000215604","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,22]]}}}